RT Journal Article SR Electronic T1 Antibody Responses to 3rd Dose mRNA Vaccines in Nursing Home and Assisted Living Residents JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.12.17.21267996 DO 10.1101/2021.12.17.21267996 A1 Ali Zhang A1 Jessica A. Breznik A1 Rumi Clare A1 Ishac Nazy A1 Matthew S. Miller A1 Dawn M. E. Bowdish A1 Andrew P. Costa YR 2021 UL http://medrxiv.org/content/early/2021/12/18/2021.12.17.21267996.abstract AB A comparison of SARS-CoV-2 wild-type and the beta variant virus neutralization capacity between 2 and 3 mRNA vaccine series in nursing home residents, and between nursing home and assisted living residents strongly supports 3rd dose vaccine recommendations, and equivalent polices for nursing homes and assisted living settings. Findings suggest that residents mount a robust humoral response to a 3rd mRNA vaccination, and have greater neuralization capacity compared to a 2 dose series.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by a grant from Canadian COVID-19 Immunity Task Force and Public Health Agency of Canada.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All protocols were approved by the Hamilton Integrated Research Ethics Board, and informed consent was obtained (HiREB #13059).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors